Review top news and interview highlights from the week ending January 5, 2024.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.
The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.
The FDA and EMA have accepted marketing authorization applications and decisions are pending.
The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.
ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.